Navigation Links
Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
Date:10/7/2008

Technology expected to aid drug discovery by allowing for the rapid

synthesis of molecules using a single reaction

ST. LOUIS, Oct. 7 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) is pleased to announce that it has signed an exclusive licensing agreement with the University of Illinois at Urbana-Champaign allowing Sigma-Aldrich to offer research quantities of powerful new boronic acid surrogates for use in Suzuki-Miyaura coupling to researchers worldwide (http://sigma-aldrich.com/mida). Under the terms of the agreement, Sigma-Aldrich can also satisfy commercial-scale requests for these surrogates from its manufacturing customers.

Developed by Professor Martin Burke and co-workers, the technology has powerful implications for drug discovery, where the ability to quickly create large sets of related small molecules for use in screening is critical. The advancement relies on the use of a simple, low-cost, and environmentally-friendly ligand (N-methyliminodiacetic acid, "MIDA") that reversibly modulates boronic acids toward cross-coupling. The MIDA-ligated boronic acid building blocks can be used to construct target molecules using a single cross-coupling reaction in an iterative process, in a fashion resembling peptide synthesis. Complex bioactive molecules can also be efficiently constructed, as demonstrated in recent publications from the Burke research group in 2007 and 2008.

"Sigma-Aldrich has a nearly 40-year history of developing boron reagents for use by the chemical community, and we are delighted to maintain our leadership position in this area by garnering access to this potent technology," said Nate Wallock, Chemistry technology transfer manager at Sigma-Aldrich. "In collaboration with the Burke group, our R&D groups have actively developed the syntheses of dozens of MIDA boronic acid derivatives, many of which will be available globally in the coming weeks. We expect to offer a broad set of these 'off-the-shelf' MIDA synthons, which will enable chemists to rapidly assemble complex chemical architectures using a single palladium-catalyzed reaction."

"This partnership brings together the strengths of a leader in the chemical industry with a first class research university ensuring that both researchers and commercial entities have access to these novel derivatives," stated Eric Payne, technology manager of the Office of Technology Management (OTM), of the University of Illinois at Urbana-Champaign. "We look forward to continuing to partner with Sigma-Aldrich on a wide range of new reagents."

In addition to applications in iterative cross-coupling, MIDA-protected boronic acids (i.e., MIDA boronate esters) have substantially enhanced shelf lives relative to the free boronic acids that often suffer from limited bench top stability. Also, unlike other boronic acid derivatives that may exhibit reduced reactivity relative to their boronic acid counterparts, the MIDA boronate esters are cleaved under exceptionally mild conditions to release the coupling-active boronic acid.

The MIDA technology highlights Sigma-Aldrich's continuing efforts to expand its portfolio of proprietary catalysts, ligands, and organometallic building blocks for use in cross-coupling. Detailed application information on this technology and related products can be found at http://sigma-aldrich.com/mida.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning website at http://www.sigma-aldrich.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
2. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
3. Sigma-Aldrich to Present at the UBS 2008 Global Life Sciences Conference on September 24, 2008
4. Sigma-Aldrich Launches Breakthrough Genome-Editing Tools
5. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
6. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
7. Sigma-Aldrich (Nasdaq: SIAL) Reports 16.7% Gain in Q2 2008 Diluted EPS. Q2 2008 Sales Rise 14.4%. 2008 Diluted EPS Forecast Raised $.05 to $2.62-$2.72.
8. Sigma-Aldrich Corporations 2nd Quarter 2008 Earnings Conference Call
9. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
10. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
11. Sigma-Aldrich Announces Collaboration to Develop Monoclonal Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
Breaking Biology Technology:
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
Breaking Biology News(10 mins):